Please assess the completion status of the following clinical trial:

Trial Title: Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of breast cancer established by biopsy.~* Normal kidney function~* Normal LVEF evaluated by MUGA Scan~* \>18 years of age~* Good performance status defined by ECOG scale of 0 or 1~* Consent~* Women of childbearing potential must have a negative pregnancy test.~* Use of effective means of contraception in subjects of child-bearing potential while on treatment and for at least 3 months thereafter.~* Peripheral Neuropathy: must be \< grade 1~* Hematologic (minimal values)~* Absolute neutrophil count \>1,500/mm3~* Hemoglobin \>8.0 g/dl~* Platelet count \>100,000/mm3~* Hepatic~* Total bilirubin \<ULN~* AST, ALT, Alkaline Phosphatase must be within range~Exclusion Criteria:~* Patients with locally advanced breast cancer with skin ulcerations~* Stage IV breast cancer~* Inflammatory breast cancer~* Allergy to any component of the treatment regimen~* Women who are breast feeding~* Pregnancy or refusal to use effective contraception~* Inability to comply with study and/or follow-up procedures.~* Current, recent, or planned participation in a experimental drug study~* Blood pressure of \>150/100 mmHg. Essential hypertension well controlled with anti hypertensives is not an exclusion criterion.~* unstable angina~* New York Heart Association Grade II or greater congestive heart failure~* history of myocardial infarction within 6 months~* history of stroke within 6 months~* Clinical significant peripheral vascular disease~* Evidence of bleeding diathesis or coagulopathy~* Presence of central nervous system or brain metastasis~* major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0~* Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days prior to day 0~* Pregnant or lactating~* Urine protein: creatinine ratio \>1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Serious, non-healing wound, ulcer, or bone fracture

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention: Dtx Cyclophosphamide Bev (Type: EXPERIMENTAL): Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).